Nurix Therapeutics, Inc.
NRIXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NRIX. That does not mean none is planned.
Get an email about NRIX's next catalysts
Track Nurix Therapeutics (NRIX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NX-5948 | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Frequently asked questions
What is in Nurix Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Nurix Therapeutics, Inc.'s (NRIX) pipeline across Phase 3. Its lead program is NX-5948 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nurix Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Nurix Therapeutics, Inc. (NRIX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NRIX biotech catalysts?→
Add NRIX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nurix Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.